AEON Biopharma, Inc.
AEON
$0.75
-$0.07-7.98%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -23.36% | -1.90% | -32.78% | -43.87% | -51.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.04% | -44.30% | -61.95% | -50.90% | -71.88% |
| Operating Income | 27.04% | 44.30% | 61.95% | 50.90% | 71.88% |
| Income Before Tax | 26.46% | -104.05% | 107.71% | 107.93% | 98.10% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 26.46% | -104.05% | 107.71% | 107.93% | 98.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.46% | -104.05% | 107.71% | 107.93% | 98.10% |
| EBIT | 27.04% | 44.30% | 61.95% | 50.90% | 71.88% |
| EBITDA | 27.06% | 44.39% | 62.04% | 50.99% | 72.00% |
| EPS Basic | 96.53% | -100.20% | 101.00% | 107.39% | 97.10% |
| Normalized Basic EPS | 96.59% | -121.43% | 101.74% | -44.64% | 83.64% |
| EPS Diluted | 96.53% | -100.20% | 101.00% | 106.81% | 97.10% |
| Normalized Diluted EPS | 96.59% | -121.43% | 101.74% | -44.36% | 83.64% |
| Average Basic Shares Outstanding | 2,018.52% | 1,954.61% | 669.43% | 7.40% | -34.50% |
| Average Diluted Shares Outstanding | 2,018.52% | 1,954.61% | 669.43% | 7.60% | -34.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |